Shares of Obalon Therapeutics, Inc. (NASDAQ:OBLN) fell -7.02% to reach at $0.74 during previous trading session. The company has experienced volume of 1,005,174 shares while on average the company has a capacity of trading 4.55M share.
Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, declares the appointment of Bob MacDonald to the newly created position of Chief Retail Officer.
In this role, Mr. MacDonald will be mainly responsible for establishing Obalon-owned retail clinics focused on weight loss utilizing the Obalon Balloon System.
“Bob’s outstanding experience in developing a successful national chain of aesthetic retail medical clinics for Sono Bello is a natural fit for Obalon, as we implement a retail-focused program to bring our proven weight loss solution to more patients,” said William J. Plovanic, Obalon’s President and Chief Financial Officer. “His proven ability to build and manage consumer-driven businesses provides an important skill set to our management team as we embark on the Company’s next chapter.”
“I am delighted to join the Obalon team, and to begin pursuing the strong consumer interest in the Obalon Balloon System, to more efficiently convert patient interest into actively treated patients,” said Mr. MacDonald.
“The Company’s program on the retail medicine segment is an exciting proposition, and I am looking forward to executing on our mission to assist obese individuals lose weight, look great, feel great and improve their overall health with our novel FDA-approved technology.”
With over 25 years of corporate development and management experience, Mr. MacDonald has been assisting retailers and consumer services companies develop and execute strategies to acquire new customers, expand into new markets, and drive profitable growth. In his most recent role, Mr. MacDonald was VP of Growth for Sono Bello, where he expanded the network of cosmetic surgery clinics from 16 in 2016 to over 40 in 2019.
He was responsible for real estate, construction, staffing, and operational ramp-up for all new clinics, opening up 15 new markets in the Midwest, mid-Atlantic, and Southwest regions. Mr. MacDonald was also responsible for the launch and testing of new products and services within Sono Bello, counting the Obalon Balloon System.
Before Sono Bello, he held both corporate strategy and management leadership roles at Staples (7 years) and McDonald’s (10 years), where he led the operational turn-around of over 800 McDonald’s restaurants.
Mr. MacDonald also has over 10 years of experience in management consulting with Ernst & Young and Oliver Wyman, and is presently working as an independent consultant, where his clients have included Wal-Mart and Comcast. Mr. MacDonald holds a BA degree in Economics from the University of Notre Dame, and earned his MBA from Harvard Business School.
As part of the transition to a revised, more focused commercial strategy, Obalon continues to improve the efficiency of its operations and reduce operating expenses. The Company has offered voluntary separation packages to about 15 employees, counting several senior executives. No assurances can be given that all employees offered these packages will accept.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) holds the market capitalization of $25.30M along with 32.00M outstanding shares. During the last trade, stock’s minimum price has been reached out at $0.71 while the maximum trading price moved at $0.80. Currently the stock price is moving 98.65% off from the highest level of twelve months and -80.14% above from twelve months low. Obalon Therapeutics, Inc. (NASDAQ:OBLN) marked 52-week highest price level of $3.70 on Jul 31, 2018 and 52-week lowest price level of $0.37 on Aug 6, 2018.
As of current trade, Obalon Therapeutics, Inc. (NASDAQ:OBLN) has shown weekly downbeat performance of -31.85%. Its six months performance indicated a bearish -57.27% movement while its yearly performance reflected a negative trend of -66.50%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -61.81%. Shares of Obalon Therapeutics, Inc. (NASDAQ:OBLN) currently have an ABR of 2.50, derived from a total of 4 opinions. The company’s price sits 9.52% above from its 50-day moving average of $0.7305 and -57.03% below from the stock’s 200-day moving average of $1.3986. The company has Relative Strength Index (RSI 14) of 46.33 along with Average True Range (ATR 14) of 0.24. Its weekly and monthly volatility is 16.71%, 29.37% respectively. The company’s beta value is at 0.
Obalon Therapeutics, Inc. currently has a PEG ratio of 0 where as its P/E ratio is 0. The company’s price to sales ratio for trailing twelve months is 2.66 and price to book ratio for most recent quarter is 2.82, whereas price to cash per share for the most recent quarter is 1.02. Obalon Therapeutics, Inc. (NASDAQ:OBLN)’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 1.10 along with current ratio for most recent quarter of 1.20. Total debt to equity ratio of the company for most recent quarter is 3.08 whereas long term debt to equity ratio for most recent quarter is 0.00. Obalon Therapeutics, Inc. (NASDAQ:OBLN) has a Return on Assets of -101.60%. The company currently has a Return on Equity of -240.30% and Return on Investment of -160.70%.